Prognosis of Interventional Therapy Combined with Targeted Therapy and Immune Checkpoint Inhibitors in Patients with Recurrent Dual-Phenotype versus Conventional Hepatocellular Carcinoma: A Retrospective Cohort Study

Background Dual-phenotype hepatocellular carcinoma (DPHCC) is a rare subtype of HCC that co-expresses hepatocellular and cholangiocellular immunohistochemical markers and exhibits high aggressiveness. Evidence regarding the prognosis of patients with postoperative recurrent DPHCC receiving interventional therapy combined with targeted therapy and immune checkpoint inhibitors (ICIs) remains scarce. Methods In this retrospective cohort study, 35 patients with postoperative recurrent HCC treated at Xiamen Hospital of Traditional Chinese Medicine between January 2019 and March 2026 were analyzed; all received interventional therapy (transarterial chemoembolization [TACE] or hepatic arterial infusion chemotherapy [HAIC]) combined with targeted therapy and ICIs. Patients were classified into a DPHCC group (n = 17) and a conventional HCC group (n = 18) according to pathological immunohistochemical findings. The primary endpoints were post-recurrence overall survival (OS) and progression-free survival (PFS). Survival curves were estimated using the Kaplan–Meier method and compared using the log-rank test. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using Cox proportional hazards models. Restricted mean survival time (RMST) was calculated to complement median survival estimates. Results Post-recurrence OS was significantly shorter in the DPHCC group than in the conventional group (median, 18.2 vs. 36.8 months; HR, 2.75; 95% CI, 1.15–6.59; P = 0.019), and the RMST for OS at 12 months was correspondingly shorter in the DPHCC group. Post-recurrence PFS also tended to be shorter in the DPHCC group (median, 4.6 vs. 9.8 months; HR, 1.78; 95% CI, 0.86–3.68; P = 0.120). Conclusions Among patients with postoperative recurrent HCC treated with interventional therapy combined with targeted therapy and ICIs, the dual-phenotype subtype was associated with poorer post-recurrence survival. DPHCC may represent a high-risk subtype requiring closer surveillance and more aggressive systemic treatment strategies after postoperative recurrence.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-18
DOI
https://doi.org/10.21203/rs.3.rs-11527037/v1
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Prognosis of Interventional Therapy Combined with Targeted Therapy and Immune Checkpoint Inhibitors in Patients with Recurrent Dual-Phenotype versus Conventional Hepatocellular Carcinoma: A Retrospective Cohort Study

P. Li, XiWang Lin, Heping Zhu, Zhenyu Yin et al.
4 links
Research Square
Hepatocellular Carcinoma Treatment and Prognosis
preprint

Prognosis of Interventional Therapy Combined with Targeted Therapy and Immune Checkpoint Inhibitors in Patients with Recurrent Dual-Phenotype versus Conventional Hepatocellular Carcinoma: A Retrospective Cohort Study

P. Li, XiWang Lin, Heping Zhu, Zhenyu Yin, ShenPing Hu
preprint en

Abstract

Background Dual-phenotype hepatocellular carcinoma (DPHCC) is a rare subtype of HCC that co-expresses hepatocellular and cholangiocellular immunohistochemical markers and exhibits high aggressiveness. Evidence regarding the prognosis of patients with postoperative recurrent DPHCC receiving interventional therapy combined with targeted therapy and immune checkpoint inhibitors (ICIs) remains scarce. Methods In this retrospective cohort study, 35 patients with postoperative recurrent HCC treated at Xiamen Hospital of Traditional Chinese Medicine between January 2019 and March 2026 were analyzed; all received interventional therapy (transarterial chemoembolization [TACE] or hepatic arterial infusion chemotherapy [HAIC]) combined with targeted therapy and ICIs. Patients were classified into a DPHCC group (n = 17) and a conventional HCC group (n = 18) according to pathological immunohistochemical findings. The primary endpoints were post-recurrence overall survival (OS) and progression-free survival (PFS). Survival curves were estimated using the Kaplan–Meier method and compared using the log-rank test. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using Cox proportional hazards models. Restricted mean survival time (RMST) was calculated to complement median survival estimates. Results Post-recurrence OS was significantly shorter in the DPHCC group than in the conventional group (median, 18.2 vs. 36.8 months; HR, 2.75; 95% CI, 1.15–6.59; P = 0.019), and the RMST for OS at 12 months was correspondingly shorter in the DPHCC group. Post-recurrence PFS also tended to be shorter in the DPHCC group (median, 4.6 vs. 9.8 months; HR, 1.78; 95% CI, 0.86–3.68; P = 0.120). Conclusions Among patients with postoperative recurrent HCC treated with interventional therapy combined with targeted therapy and ICIs, the dual-phenotype subtype was associated with poorer post-recurrence survival. DPHCC may represent a high-risk subtype requiring closer surveillance and more aggressive systemic treatment strategies after postoperative recurrence.

Research Square
Xiamen University (CN), Zhongshan Hospital of Xiamen University (CN), Children’s Hospital of Fudan University Xiamen Branch (CN)
Natural Science Foundation of Fujian Province
Good health and well-being
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon